Test method of reaction of EPHX1 genotype based COPD to NAC

Through the testing method based on EPHX1 genotype, the therapeutic effect of N-acetylcysteine ​​on COPD patients was evaluated, and differences in the efficacy of patients with different genotypes were found. It was speculated that it was related to the polymorphism of the oxidative inhibitory enzyme gene, providing information for personalized treatment of COPD. scientific basis.

CN106191281AInactive Publication Date: 2016-12-07张剑青
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
张剑青
Filing Date
2016-07-27
Publication Date
2016-12-07
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technology cannot effectively demonstrate whether N-acetylcysteine ​​antioxidant therapy has different effects on COPD patients with different EPHX1 genotypes, resulting in an unclear role of NAC in the treatment of COPD.

Method used

Using a test method based on EPHX1 genotype, DNA was extracted by phenol/chloroform method, polymerase chain reaction PCR amplification, polyacrylamide electrophoresis and laser scanning automatic DNA sequencing, and divided into four mEPH gene activity types, followed by NAC treatment and FEV1, SGRQ and the number of acute exacerbations were recorded, and statistical analysis was performed using Quanto and SPSS software to evaluate the effect of NAC treatment.

Benefits of technology

Through this method, it was found that COPD patients with slow and very slow EPHX1 gene activity had significant improvements in FEV1, SGRQ symptom scores and annual acute exacerbation rates after NAC treatment, indicating that NAC treatment has different effects on COPD patients with different EPHX1 genotypes, inferring oxidative inhibition. Enzyme gene polymorphisms are related to therapeutic efficacy, laying the foundation for pharmacogenomics technology in the personalized treatment of COPD.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a test method of reaction of EPHX1 genotype based COPD to NAC. The test method comprises the following steps: extracting a DNA by a phenol / chloroform method and sequencing, dividing COPD patients into slow and very slow gene activity group and a quick and normal gene activity group according to EPHX1 gene polymorphism, giving 600 mg Bid of NAC for 1 year to both groups, performing baseline measurement of pulmonary function parameters, completing SGRQ and 6MWT, measuring FVC and FEV1 at a follow-up day every 12 weeks, completingSGRQ and 6MWT in 24 and 48 weeks, and recording the number of acute exacerbationof COPD in one year. The data were statistically analyzed with SPSS. The results show that NAC is effective in the treatment of slow and very slow EPHX1 gene activityCOPD patients. The test method provided by the invention provides a solid basis for demonstrating the effect and mechanism of NAC based on pharmacogenomics in the individualized treatment of COPD.
Need to check novelty before this filing date? Find Prior Art